Evaluation of Two Inflammation-Based Prognostic Scores in Patients with Resectable Gallbladder Carcinoma

Abstract

GPS is superior to NLR with respect to its prognostic value for patients with GBC after surgery with curative intent. GPS is not only associated with tumor progression but is also an independent marker of poor prognosis.

MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway

“…9 Therefore, the identification of novel methods that can effectively inhibit GBC growth and metastasis is needed. Although lncRNAs were initially argued to be spurious transcriptional noise, recent evidence suggests that they may play a major biological role in cellular development and human diseases.…”

“…[1][2][3][4][5][6][7][8][9] Curative resection is the only cure for this highly lethal malignancy. However, owing to its non-specific symptoms and highly invasive nature, most patients are at an advanced stage when they are diagnosed.…”

“…The mean survival for this malignancy ranges from 5.2 to 24.4 mo, according to different reports. 9,[11][12][13] Most of these patients die from tumor metastasis and recurrence. Therefore, an understanding of the molecular mechanisms of GBC metastasis and recurrence is indispensable for the development of effective adjuvant therapy.…”

Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma

“…Previous study has shown the close relationship between blood system-mediated inflammation and GBC [6]. The relative changes of body inflammatory reaction and immune state are closely related to the occurrence and development of tumors, thereby affecting the prognosis of the tumors [7].…”

Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study

“…Gallbladder cancer (GBC) is the most common biliary tract malignancy and the seventh most common gastrointestinal cancer [1]. The Surveillance, Epidemiology, and End Results (SEER) program estimates the incidence of GBC at 2.5 per 100,000 persons.…”